The Walter and Eliza Institute of Medical Research, a leading biomedical research center in Australia, recently selected U.S.-based, multinational IQVIA (NYSE: IQV)—the world’s largest clinical research organization or CRO—to manage COVID SHIELD, a Phase II/III randomized, double-blinded clinical study of preventive care for frontline health workers fighting the COVID-19 pandemic.
What is the COVID SHEILD?
The COVID SHEILD clinical study was organized to test an expanded indication for generic hydroxychloroquine as a prophylactic treatment to prevent high-risk healthcare workers from contracting COVID-19. The study will be conducted at local hospitals across Australia—the investigational site staff will administer either the study drug or a placebo to approximately 2,250 healthcare professionals who are caring for COVID-19 patients.
State-of-the-Art Digital Study
IQIVIA will streamline this study without placing undue risks and burden on the frontline healthcare workers or clinical teams by using virtual clinical tools and technologies. For example, the CRO and sites will make sure of remote monitoring, eConsent, eTMF and e-source technologies. While actual participating, healthcare workers involved with this study will be located across several Australian states such as Victoria, New South Wales and South Australia and the Australian Capital Territory. A vast expanse of terrain, the technologies will transfer digital data and documents at near light speed. Interestingly enough, none of these technologies are new; IQVIA has been investing in a number of these solutions for many years.
Principal Investigator Pleased
Marc Pellegrini, principal investigator for Walter and Eliza Hall Institute of Medical Research, reminds all of the importance of keeping healthcare workers safe as they care for those infected with the highly contagious SARS-CoV-2, the virus behind COVID-19. He commented, “We are pleased to work with IQVIA in this fight against COVID-19 and are hopeful this Australian-first trial will provide a definitive answer to the question of whether hydroxychloroquine is effective as a prophylaxis, or prevention, against contracting COVID-19.”
The Walter and Eliza Institute of Medical Research
The Walter and Eliza Institute of Medical Research is Australia’s oldest medical research institute. They address major health challenges of the time with a focus on cancer, immune health and infection, and development and aging. The Institute is organized around five research themes including 1) Infection, Inflammation and Immunity; 2) Cancer Research and Treatments; 3) Health Development and Aging; 4) New Medicines and Advanced Technologies; and 5) Computational Biology.
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies Human Data Science—leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science—to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With approximately 67,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures.
Marc Pellegrini, BSc, MBBS, PhD, Melbourne FRACP, Professor, Joint Division Head, Infectious Diseases and Immune Practice, principal investigator